Enlivex Therapeutics/$ENLV
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Enlivex Therapeutics
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Ticker
$ENLV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Ness Ziona, Israel
Employees
-
ISIN
IL0011319527
Website
ENLV Metrics
BasicAdvanced
$28M
-
-$0.66
0.74
-
Price and volume
Market cap
$28M
Beta
0.74
52-week high
$1.30
52-week low
$0.84
Average daily volume
82K
Financial strength
Current ratio
7.203
Quick ratio
6.964
Long term debt to equity
1.28
Total debt to equity
2.439
Profitability
EBITDA (TTM)
-14.643
Management effectiveness
Return on assets (TTM)
-34.24%
Return on equity (TTM)
-60.35%
Valuation
Price to book
1.36
Price to tangible book (TTM)
1.36
Price to free cash flow (TTM)
-1.944
Free cash flow yield (TTM)
-51.43%
Free cash flow per share (TTM)
-60.69%
Growth
Earnings per share change (TTM)
-52.41%
3-year earnings per share growth (CAGR)
-14.68%
ENLV News
AllArticlesVideos
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
GlobeNewsWire·4 weeks ago
Enlivex Selected to Present at Israeli BioMed 2025 Conference
GlobeNewsWire·2 months ago
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enlivex Therapeutics stock?
Enlivex Therapeutics (ENLV) has a market cap of $28M as of July 05, 2025.
What is the P/E ratio for Enlivex Therapeutics stock?
The price to earnings (P/E) ratio for Enlivex Therapeutics (ENLV) stock is 0 as of July 05, 2025.
Does Enlivex Therapeutics stock pay dividends?
No, Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Enlivex Therapeutics dividend payment date?
Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enlivex Therapeutics?
Enlivex Therapeutics (ENLV) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.